Replimune Group, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sushil Patel
- Full Time Employees
- 465
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Unicorn Park Drive Woburn MA United States of America 01801
- IPO Date
- Jul 20, 2018
- CIK
- 0001737953
- Website
- replimune.com
- Similar Companies
- Business
- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, develops oncolytic immunotherapies based on its proprietary RPx platform, which utilizes an engineered herpes simplex virus 1 (HSV-1) backbone to selectively replicate in and destroy tumor cells while stimulating systemic anti-tumor immune responses; its lead product candidate RP1 (vusolimogene oderparepvec) expresses GALV-GP R(-) and human GM-CSF for treating solid tumors including advanced melanoma; RP2 incorporates an anti-CTLA-4 antibody-like protein to enhance T-cell activation; and RP3 expresses multiple immune-activating transgenes including anti-CTLA-4 and immune stimulatory proteins to further potentiate immune responses against cancer. Founded in 2015 and headquartered in Woburn, Massachusetts, the company conducts operations primarily in the United States and the United Kingdom, targeting patients with solid tumors such as melanoma, skin, and other cancers through clinical-stage programs often in combination with checkpoint inhibitors like nivolumab (Opdivo). In recent developments, Replimune submitted a biologics license application (BLA) to the U.S. FDA for RP1 plus nivolumab in advanced melanoma post-anti-PD1 therapy, which received priority review before a complete response letter (CRL) in July 2025; the company resubmitted the BLA in October 2025 with additional data and analyses addressing FDA feedback, earning acceptance and a PDUFA target action date of April 10, 2026; additionally, it announced a proposed $125 million public offering of common stock in November 2024, with a 30-day underwriter option for $18.75 million more, to fund clinical development and operations.
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)
Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
How Replimune's drug got a third chance after the White House intervened
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune reaches agreement with US FDA to resubmit melanoma drug application
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
Replimune Gets Third Try at FDA Approval After Makary Departure
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1